Related Experiment Video

Updated: Jun 8, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Poly(ADP-Ribose) polymerase inhibition: "targeted" therapy for triple-negative breast cancer

Carey K Anders1, Eric P Winer, James M Ford

  • 1University of North Carolina, Chapel Hill, 27517, USA. carey_anders@med.unc.edu

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|September 23, 2010
PubMed

Insights

Poly(ADP-ribose) polymerase (PARP) inhibitors show promise for treating advanced triple-negative breast cancer (TNBC) by targeting DNA repair. Clinical trials confirm their efficacy in BRCA-deficient and TNBC, offering new therapeutic avenues.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Advanced triple-negative breast cancer (TNBC) lacks targeted therapies, unlike endocrine-sensitive or HER2-positive breast cancer.
  • Poly(ADP-ribose) polymerase (PARP) inhibitors are a novel class of targeted therapeutics.
  • PARP enzymes are crucial for DNA repair processes within cells.

Purpose of the Study:

  • To review the preclinical rationale for using PARP inhibitors in TNBC.
  • To explain the mechanism of action for PARP inhibitors.
  • To discuss clinical trial results, resistance mechanisms, and future directions for PARP inhibitors in breast cancer treatment.

Main Methods:

  • Review of preclinical models and clinical trials involving PARP inhibitors.
  • Analysis of the mechanism of action of PARP inhibition in DNA repair.
  • Examination of acquired resistance mechanisms and future therapeutic strategies.

Main Results:

  • PARP inhibition combined with BRCA-dependent DNA repair defects leads to synthetic lethality and increased cell death.
  • Preclinical models and clinical trials demonstrate the effectiveness of PARP inhibitors in BRCA-deficient and TNBC.
  • Promising results have been observed in clinical trials for advanced breast cancer.

Conclusions:

  • PARP inhibitors represent a promising targeted therapy for advanced TNBC, particularly in BRCA-deficient cases.
  • Understanding resistance mechanisms is crucial for optimizing long-term treatment efficacy.
  • Further research and development are needed to fully leverage PARP inhibitors in breast cancer therapy.

More Related Videos

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells09:24

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Published on: August 12, 2015

Utilization of the Soft Agar Colony Formation Assay to Identify Inhibitors of Tumorigenicity in Breast Cancer Cells11:06

Utilization of the Soft Agar Colony Formation Assay to Identify Inhibitors of Tumorigenicity in Breast Cancer Cells

Published on: May 20, 2015

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...